Step-by-step management of refractory gastresophageal reflux disease

Diseases of the Esophagus

Volumn 26, Issue 1, 2013, Pages 27-36

  Hershcovici, T ^a,b   Fass, R ^a,b  

^a SOUTHERN ARIZONA VA HEALTH CARE SYSTEM   (United States)

^b UNIVERSITY OF ARIZONA   (United States)

Author keywords

Esophageal impedance; Heartburn; Proton pump inhibitor; Refractory gastroesophageal reflux disease; Transient lower esophageal sphincter relaxation

Indexed keywords

4 AMINOBUTYRIC ACID B RECEPTOR STIMULATING AGENT; ALUMINUM SALT; ANTACID AGENT; GAVISCON; HISTAMINE H2 RECEPTOR ANTAGONIST; METABOTROPIC RECEPTOR 5; METABOTROPIC RECEPTOR 5 ANTAGONIST; PEPSIN A; PROTON PUMP INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SUCRALFATE; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG;

ANTIREFLUX OPERATION; DIAGNOSTIC VALUE; DRUG TREATMENT FAILURE; ENDOSCOPIC SURGERY; ENDOSCOPY; ESOPHAGUS PAIN; GASTROESOPHAGEAL REFLUX; HEARTBURN; HUMAN; IMPEDANCE; LOWER ESOPHAGUS SPHINCTER; MULTICHANNEL INTRALUMINAL IMPEDANCE; PATHOGENESIS; PATIENT COMPLIANCE; PH; PRIORITY JOURNAL; REFLUX ESOPHAGITIS; REVIEW; STOMACH ACID; STOMACH CONTENT; STOMACH PH;

ADULT; AGED; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; ESOPHAGEAL PH MONITORING; ESOPHAGEAL SPHINCTER, LOWER; ESOPHAGOSCOPY; FEMALE; GASTROESOPHAGEAL REFLUX; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; PROTON PUMP INHIBITORS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 84872127013     PISSN: 11208694     EISSN: 14422050     Source Type: Journal    
DOI: 10.1111/j.1442-2050.2011.01322.x     Document Type: Review

References (70)

1. Fass R, Sifrim D. Management of heartburn not responding to proton pump inhibitors. Gut 2009; 58: 295-309.
2. Gallup Organization. The 2000 Gallup Study of Consumers' Use of Stomach Relief Products. Princeton: Gallup Organization, 2000.
3. Chey W D, Mody R R, Wu E Q etal. Treatment patterns and symptom control in patients with GERD: US community-based survey. Curr Med Res Opin 2009; 25: 1869-78.
4. Hershcovici T, Fass R. Management of gastroesophageal reflux disease that does not respond well to proton pump inhibitors. Curr Opin Gastroenterol 2010; 26: 367-78.
5. Dean B B, Gano A D Jr, Knight K, Ofman J J, Fass R. Effectiveness of proton pump inhibitors in nonerosive reflux disease. Clin Gastroenterol Hepatol 2004; 2: 656-64.
6. Fass R, Sampliner R E. Barrett's oesophagus: optimal strategies for prevention and treatment. Drugs 2003; 63: 555-64.
7. Fass R. Persistent heartburn in a patient on proton-pump inhibitor. Clin Gastroenterol Hepatol 2008; 6: 393-400.
8. Hungin A P S, Rubin G, O'Flanagan H. Factors influencing compliance in long-term proton pump inhibitor therapy in general practice. Br J Gen Pract 1999; 49: 463-4.
9. Tack J, Koek G, Demedts I, Sifrim D, Janssens J. Gastroesophageal reflux disease poorly responsive to single-dose proton pump inhibitors in patients without Barrett's esophagus: acid reflux, bile reflux, or both? Am J Gastroenterol 2004; 99: 981-8.
10. Gasiorowska A, Navarro-Rodriguez T, Wendel C etal. Comparison of the degree of duodenogastroesophageal reflux and acid reflux between patients who failed to respond and those who were successfully treated with a proton pump inhibitor once daily. Am J Gastroenterol 2009; 104: 2005-13.
11. Rome I I I. The Functional Gastrointestinal Disorders, 3rd edn. McLean, VA: Degnon Associates, Inc., 2006.
12. Mainie I, Tutuian R, Shay S etal. Acid and non-acid reflux in patients with persistent symptoms despite acid suppressive therapy: a multicentre study using combined ambulatory impedance-pH monitoring. Gut 2006; 55: 1398-402.
13. Peghini P L, Katz P O, Bracy N A, Castell D O. Nocturnal recovery of gastric acid secretion with twice-daily dosing of proton pump inhibitors. Am J Gastroenterol 1998; 93: 763-7.
14. Nzeako U C, Murray J A. An evaluation of the clinical implications of acid breakthrough in patients on proton pump inhibitor therapy. Aliment Pharmacol Ther 2002; 16: 1309-16.
15. Fass R, Gasiorowska A. Refractory GERD: what is it? Curr Gastroenterol Rep 2008; 10: 252-7.
16. Fass R. Proton-pump inhibitor therapy in patients with gastro-oesophageal reflux disease: putative mechanisms of failure. Drugs 2007; 67: 1521-30.
17. Gunaratnam N T, Jessup T P, Inadomi J, Lascewski D P. Sub-optimal proton pump inhibitor dosing is prevalent in patients with poorly controlled gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2006; 23: 1473-7.
18. Kaltenbach T, Crockett S, Gerson L B. Are lifestyle measures effective in patients with gastroesophageal reflux disease? An evidence-based approach. Arch Intern Med 2006; 166: 965-71.
19. Kahrilas P J, Shaheen N J, Vaezi M F etal. American Gastroenterological Association Medical Position Statement on the management of gastroesophageal reflux disease. Gastroenterology 2008; 135: 1383-91, 91 e1-5.
20. Khan M, Santana J, Donnellan C, Preston C, Moayyedi P. Medical treatments in the short term management of reflux oesophagitis. Cochrane Database Syst Rev 2007; (2): CD003244.
21. Fass R, Sontag S J, Traxler B, Sostek M. Treatment of patients with persistent heartburn symptoms: a double-blind, randomized trial. Clin Gastroenterol Hepatol 2006; 4: 40-56.
22. Hatlebakk J, Katz P, Kuo B, Castell D O. Nocturnal gastric acidity and acid breakthrough on different regimens of omeprazole 40mg daily. Aliment Pharmacol Ther 1998; 12: 1235-40.
23. Sifrim D, Castell D O, Dent J, Kahrilas P J. Gastro-oesophageal reflux monitoring: review and consensus report on detection and definitions of acid, non-acid, and gas reflux. Gut 2004; 53: 1024-31.
24. Boeckxstaens G E, Smout A. Systematic review: role of acid, weakly acidic and weakly alkaline reflux in gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2010; 32: 334-43.
25. Tutuian R, Vela M F, Hill E G, Mainie I, Agrawal A, Castell D O. Characteristics of symptomatic reflux episodes on Acid suppressive therapy. Am J Gastroenterol 2008; 103: 1090-6.
26. Zerbib F, Duriez A, Roman S, Capdepont M, Mion F. Determinants of gastro-oesophageal reflux perception in patients with persistent symptoms despite proton pump inhibitors. Gut 2008; 57: 156-60.
27. Zerbib F, Roman S, Ropert A etal. Esophageal pH-impedance monitoring and symptom analysis in GERD: a study in patients off and on therapy. Am J Gastroenterol 2006; 101: 1956-63.
28. Pace F, Sangaletti O, Pallotta S, Molteni P, Porro G B. Biliary reflux and non-acid reflux are two distinct phenomena: a comparison between 24-hour multichannel intraesophageal impedance and bilirubin monitoring. Scand J Gastroenterol 2007; 42: 1031-9.
29. Slaughter J C, Goutte M, Rymer J A etal. Caution about over-interpretation of symptom indices in reflux monitoring for refractory gastroesophageal reflux disease. Clin Gastroenterol Hepatol 2011; 9: 868-74.
30. Pritchett J M, Aslam M, Slaughter J C, Ness R M, Garrett C G, Vaezi M F. Efficacy of esophageal impedance/pH monitoring in patients with refractory gastroesophageal reflux disease, on and off therapy. Clin Gastroenterol Hepatol 2009; 7: 743-8.
31. Poh C H, Gasiorowska A, Navarro-Rodriguez T etal. Upper GI tract findings in patients with heartburn in whom proton pump inhibitor treatment failed versus those not receiving antireflux treatment. Gastrointest Endosc 2010; 71: 28-34.
32. van Malenstein H, Farre R, Sifrim D. Esophageal dilated intercellular spaces (DIS) and nonerosive reflux disease. Am J Gastroenterol 2008; 103: 1021-8.
33. Vela M F, Craft B M, Sharma N, Freeman J, Hazen-Martin D. Refractory heartburn: comparison of intercellular space diameter in documented GERD vs. functional heartburn. Am J Gastroenterol 2011; 106: 844-50.
34. Bautista J M, Wong W M, Pulliam G, Esquivel R F, Fass R. The value of ambulatory 24hr esophageal pH monitoring in clinical practice in patients who were referred with persistent gastroesophageal reflux disease (GERD)-related symptoms while on standard dose antireflux medications. Dig Dis Sci 2005; 50: 1909-15.
35. Karamanolis G, Vanuytsel T, Sifrim D etal. Yield of 24-hour esophageal pH and bilitec monitoring in patients with persisting symptoms on PPI therapy. Dig Dis Sci 2008; 53: 2387-93.
36. Charbel S, Khandwala F, Vaezi M F. The role of esophageal pH monitoring in symptomatic patients on PPI therapy. Am J Gastroenterol 2005; 100: 283-9.
37. Koek G H, Tack J, Sifrim D, Lerut T, Janssens J. The role of acid and duodenal gastroesophageal reflux in symptomatic GERD. Am J Gastroenterol 2001; 96: 2033-40.
38. Sharma N, Agrawal A, Freeman J, Vela M F, Castell D. An analysis of persistent symptoms in acid-suppressed patients undergoing impedance-pH monitoring. Clin Gastroenterol Hepatol 2008; 6: 521-4.
39. Hirano I, Zhang X, Pandolfino J E, Kahrilas P. Bravo pH capsule monitoring with and without proton pump inhibitor therapy. Clin Gastroenterol Hepatol 2005; 3: 1083-8.
40. Fass R, Hixson L J, Ciccolo M L, Gordon P, Hunter G, Rappaport W. Contemporary medical therapy for gastroesophageal reflux disease. Am Fam Physician 1997; 55: 205-12.
41. Peghini P L, Katz P O, Castell D O. Ranitidine controls nocturnal gastric acid breakthrough on omeprazole: a controlled study in normal subjects. Gastroenterology 1998; 115: 1335-9.
42. Fackler W K, Ours T M, Vaezi M F, Richter J E. Long-term effect of H2RA therapy on nocturnal gastric acid breakthrough. Gastroenterology 2002; 122: 625-32.
43. Blackshaw L A. Receptors and transmission in the brain-gut axis: potential for novel therapies. IV. GABA(B) receptors in the brain-gastroesophageal axis. Am J Physiol 2001; 281: G311-15.
44. Frisby C L, Mattsson J P, Jensen J M, Lehmann A, Dent J, Blackshaw L A. Inhibition of transient lower esophageal sphincter relaxation and gastroesophageal reflux by metabotropic glutamate receptor ligands. Gastroenterology 2005; 129: 995-1004.
45. Zhang Q, Lehmann A, Ridga R, Dent J, Holloway R H. Control of transient lower oesophageal sphincter relaxations and reflux by the GABA(B) agonist baclofen in patients with gastro-oesophageal reflux disease. Gut 2002; 50: 19-24.
46. Lidums I, Lehmann A, Checklin H, Dent J, Holloway R H. Control of transient lower esophageal sphincter relaxations and reflux by the GABA(B) agonist baclofen in normal subjects. Gastroenterology 2000; 118: 7-13.
47. Omari T I, Benninga M A, Sansom L, Butler R N, Dent J, Davidson G P. Effect of baclofen on esophagogastric motility and gastroesophageal reflux in children with gastroesophageal reflux disease: a randomized controlled trial. J Pediatr 2006; 149: 436-8.
48. Vela M F, Tutuian R, Katz P O, Castell D O. Baclofen decreases acid and non-acid post-prandial gastro-oesophageal reflux measured by combined multichannel intraluminal impedance and pH. Aliment Pharmacol Ther 2003; 17: 243-51.
49. Koek G H, Sifrim D, Lerut T, Janssens J, Tack J. Effect of the GABA(B) agonist baclofen in patients with symptoms and duodeno-gastro-oesophageal reflux refractory to proton pump inhibitors. Gut 2003; 52: 1397-402.
50. Gerson L B, Huff F J, Hila A etal. Arbaclofen placarbil decreases postprandial reflux in patients with gastroesophageal reflux disease. Am J Gastroenterol 2010; 105: 1266-75.
51. Boeckxstaens G E, Beaumont H, Mertens V etal. Effects of lesogaberan on reflux and lower esophageal sphincter function in patients with gastroesophageal reflux disease. Gastroenterology 2010; 139: 409-17.
52. Boeckxstaens G E, Beaumont H, Hatlebakk J G, Silberg D G, Adler J, Denison H. Efficacy and tolerability of the novel reflux inhibitor, AZD3355, as add-on treatment in GERD patients with symptoms despite proton pump inhibitor therapy. Gastroenterology 2009; 136: A436.
53. Hershcovici T, Fass R. Transient lower oesophageal sphincter relaxation reducers - have we hit a brick wall? Aliment Pharmacol Ther 2011; 33: 1256-7, author reply 7-8.
54. Keywood C, Wakefield M, Tack J. A proof-of-concept study evaluating the effect of ADX10059, a metabotropic glutamate receptor-5 negative allosteric modulator, on acid exposure and symptoms in gastro-oesophageal reflux disease. Gut 2009; 58: 1192-9.
55. Fass R, Shapiro M, Dekel R, Sewell J. Systematic review: proton-pump inhibitor failure in gastro-oesophageal reflux disease - where next? Aliment Pharmacol Ther 2005; 22: 79-94.
56. Handa M, Mine K, Yamamoto H etal. Antidepressant treatment of patients with diffuse esophageal spasm: a psychosomatic approach. J Clin Gastroenterol 1999; 28: 228-32.
57. Clouse R E, Lustman P J, Eckert T C, Ferney D M, Griffith L S. Low-dose trazodone for symptomatic patients with esophageal contraction abnormalities. A double-blind, placebo-controlled trial. Gastroenterology 1987; 92: 1027-36.
58. del Genio G, Tolone S, del Genio F etal. Total fundoplication controls acid and nonacid reflux: evaluation by pre- and postoperative 24-h pH-multichannel intraluminal impedance. Surg Endosc 2008; 22: 2518-23.
59. Rosenthal R, Peterli R, Guenin M O, van Flüe M, Ackermann C. Laparoscopic antireflux surgery: long-term outcomes and quality of life. J Laparoendosc Adv Surg Tech A 2006; 16: 557-61.
60. Antoniou S A, Delivorias P, Antoniou G A etal. Symptom-focused results after laparoscopic fundoplication for refractory gastroesophageal reflux disease - a prospective study. Langenbecks Arch Surg 2008; 393: 979-84.
61. Mainie I, Tutuian R, Agrawal A, Adams D, Castell D O. Combined multichannel intraluminal impedance-pH monitoring to select patients with persistent gastro-oesophageal reflux for laparoscopic Nissen fundoplication. Br J Surg 2006; 93: 1483-7.
62. del Genio G, Tolone S, del Genio F etal. Prospective assessment of patient selection for antireflux surgery by combined multichannel intraluminal impedance pH monitoring. J Gastrointest Surg 2008; 12: 1491-6.
63. Louis H, Deviere J. Ensocopic-endoluminal therapies. A critical appraisal. Best Pract Res Clin Gastroenterol 2010; 24: 969-79.
64. Cadiere G B, Buset M, Muls V etal. Antireflux transoral incisionless fundoplication using EsophyX: 12-month results of a prospective multicenter study. World J Surg 2008; 32: 1676-88.
65. Hoppo T, Immanuel A, Schuchert M etal. Transoral incisionless fundoplication 2.0 procedure using EsophyX for gastroesophageal reflux disease. J Gastrointest Surg 2010; 14: 1895-901.
66. Kim M S, Holloway R H, Dent J, Utley D S. Radiofrequency energy delivery to the gastric cardia inhibits triggering of transient lower esophageal sphincter relaxation and gastroesophageal reflux in dogs. Gastrointest Endosc 2003; 57: 17-22.
67. Arts J, Sifrim D, Rutgeerts P, Lerut A, Janssens J, Tack J. Influence of radiofrequency energy delivery at the gastroesophageal junction (the Stretta procedure) on symptoms, acid exposure, and esophageal sensitivity to acid perfusion in gastroesophagal reflux disease. Dig Dis Sci 2007; 52: 2170-7.
68. Corley D A, Katz P, Wo J M etal. Improvement of gastroesophageal reflux symptoms after radiofrequency energy: a randomized, sham-controlled trial. Gastroenterology 2003; 125: 668-76.
69. Dickman R, Schiff E, Holland A etal. Clinical trial: acupuncture vs. doubling the proton pump inhibitor dose in refractory heartburn. Aliment Pharmacol Ther 2007; 26: 1333-44.
70. Nojkov B, Rubenstein J H, Adlis S A etal. The influence of co-morbid IBS and psychological distress on outcomes and quality of life following PPI therapy in patients with gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2008; 27: 473-82.